A Solution for Parkinson’s Patients Impacted by Debilitating Episodes of Freezing of Gait (FoG)

Increasing Independence, Lowering Risk of Falls, Improving Quality of Life, Lowering Healthcare Costs and Lowering the Burden on Caregivers*

Parkinson's Disease affects over 10 million people worldwide, leading to a significant loss of motor functions that impairs daily living.

Freezing of Gait (FoG) — the sudden and unexpected inability to move forward while walking – is one of the most debilitating aspects of Parkinson’s Disease.

FoG affects nearly 50% of people with Parkinson's, often resulting in falls, injuries, and a loss of independence.  Freezing of Gait presents a huge burden on patients, caregivers and the healthcare system. 

By 2030 global treatment sales for Parkinson’s Disease is are expected to exceed $12 Billion. Adult Falls in the US cost the Healthcare System over $50 Billion/Year.

Fortis’ response to this unmet need, is a groundbreaking, non-invasive, FDA Class II  De Novo medical device designed to reduce the number of episodes and severity of FoG events a Parkinson’s patient  may experience*.

The FDA has recognized the value of Fortis’ solution and designated cueStim a Breakthrough Technology Device. In addition, the FDA has added cueStim to its very exclusive TAP pilot program which is intended to help breakthrough therapies get to market on an accelerated basis.